Historical Perspectives and Memories of Progressive Supranuclear Palsy

Abstract

Parkinsonism recalls James Parkinson of London and his description of six patients with “paralysis agitans” in 1817, which neurologist Jean-Marie Charcot renamed Parkinson disease. Its variants, referred to as atypical parkinsonian disorders, are the subject of this issue of Seminars in Neurology through which we continue a journey toward understanding the pathogenesis of these diverse neurodegenerative diseases that are sometimes genetically determined, but are more often sporadic and without familial occurrence.

Keywords

progressive supranuclear palsy - tauopathy - amyotrophic lateral sclerosis/parkinsonism dementia complex - prion

• References

• 1 Wherrett JR. In memoriam: John Clifford Richardson. Can J Neurol Sci 1986; 13: 292-293
• 2 Baxter DW, Buettner-Ennever JA, Sharpe JA, Leigh RJ. Jerzy Olszewski: cartographer of the brain stem reticular formation. Neurology 1987; 37 (12) 1881-1882
• 3 Colosimo C. Where are they now? An interview with Dr. John Steele. MDS Moving Along 2010; 14: 1-8
• 4 History of Medicine Archives. An oral history by J. Clifford Richardson conducted for the University of Toronto Faculty of Medicine. Toronto, Canada: Hannah Institute, University of Toronto Archives; 1982
• 5 Chavany JA, van Bogaert L, Godlewski S. Sur un syndrome de rigidité a predominance axiale, avec perturbation des automatismes oculopalpebraux d'origine encephalitique. Presse Med 1951; 59 (45) 958-962
• 6 Verhaart WJ. Degeneration of the brain stem reticular formation, other parts of the brain stem and the cerebellum; an example of heterogenous systemic degeneration of the central nervous system. J Neuropathol Exp Neurol 1958; 17 (2) 382-391
• 7 Brusa A. Degenerescence plurisystematisee du nevraxe, de charactere sporadique, a debut tardif et evolution subaigue. Rev Neurol (Paris) 1961; 104: 412-429
• 8 Neumann MA. Heterogeneous system degeneration with particular involvement of the reticular substance: Correlation with neurologic disorders and the concept of the Creutzfeld-Jakob disease. J Neuropathol Exp Neurol 1961; 20: 316
• 9 Dickens C, Collins W. The Lazy Tour of Two Idle Apprentices. London, UK: Chapman & Hall; 1890
• 10 Williams DR, de Silva R, Paviour DC , et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005; 128 (Pt 6) 1247-1258
• 11 Williams DR, Lees AJ, Wherrett JR, Steele JC. J. Clifford Richardson and 50 years of progressive supranuclear palsy. Neurology 2008; 70 (7) 566-573
• 12 Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359
• 13 Barbeau A. Degenerescence plurisystematisee du nevraxe. Syndrome de Steele-Richardson-Olszewski. Un Med Can 1965; 94: 715-718
• 14 Geddes JF, Hughes AJ, Lees AJ, Daniel SE. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of recent cases of postencephalitic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonism-dementia complex. Brain 1993; 116 (Pt 1): 281-302
• 15 Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8 (3) 270-279
• 16 Respondek G. (2013) Accuracy of clinical diagnostic criteria of PSP. Paper presented at: 17th International Congress of Parkinson's Disease and Movement Disorders; June 16–20, 2013; Sydney, Australia
• 17 Steele JC, Caparros-Lefebvre D, Lees AJ, Sacks OW. Progressive supranuclear palsy and its relation to pacific foci of the parkinsonism-dementia complex and Guadeloupean parkinsonism. Parkinsonism Relat Disord 2002; 9 (1) 39-54
• 18 Gardiner RC, Boxer AL, Trujillo A , et al. Intrinsic connectivity network disruptions in progressive supranuclear palsy. Ann Neurol 2013; 73 (5) 603-605
• 19 Hadlow WJ. Scrapie and kuru. Lancet 1959; 2: 289-290
• 20 Eklund CM, Hadlow WJ, Kennedy RC. Some properties of scrapie agent and its behavior in mice. Proc Soc Exp Biol 1963; 112: 974-979
• 21 Kaufman SK, Diamond MI. Prion-like propagation of protein aggregation and related therapeutic strategies. Neurotherapeutics 2013; 10 (3) 371-382
• 22 Clavaguera F, Akatsu H, Fraser G , et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci U S A 2013; 110 (23) 9535-9540
• 23 Richardson JC, Steele J, Olszewski J. Supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia: a clinical report on eight cases of “heterogenous system degeneration”. Trans Am Neurol Assoc 1963; 88: 25-29
• 24 Olszewski J, Steele J, Richardson JC. Pathological report on six cases of heterogeneous system degeneration. J Neuropathol Exp Neurol 1963; 23: 87-188
• 25 Hirano A, Malamud N, Kurland LT. Parkinsonism-dementia complex, an endemic disease on the island of Guam. II. Pathological features. Brain 1961; 84: 662-679
• 26 Hirano A, Kurland LT, Krooth RS, Lessell S. Parkinsonism-dementia complex, an endemic disease on the island of Guam. I. Clinical features. Brain 1961; 84: 642-661
• 27 Steele JC. Progressive supranuclear palsy. Brain 1972; 95 (4) 693-704
• 28 Steele JC. Progressive supranuclear palsy. Report of a Thai patient. J Med Assoc Thai 1970; 53 (5) 364-368
• 29 Steele JC. Progressive supranuclear palsy. In: Vinken PJ, Bruyn GW, DeJong JMBV, , eds. Handbook of Clinical Neurology. Amsterdam, The Netherlands: North-Holland Publishing Company; 1975: 217-229
• 30 Steele JC. Introduction. In: Litvan I, Agid Y, , eds. Progressive Supranuclear Palsy: Clinical and Research Approaches. Oxford, UK: Oxford University Press; 1992: 1-110
• 31 Steele JC. Progressive supranuclear palsy. Historical notes. J Neural Transm Suppl 1994; 42: 3-14
• 32 Höglinger GU, Melhem NM, Dickson DW , et al; PSP Genetics Study Group. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nat Genet 2011; 43 (7) 699-705
• 33 Steele JC. Parkinsonism-dementia complex of Guam. Mov Disord 2005; 20 (20) (Suppl. 12) S99-S107
• 34 Miklossy J, Steele JC, Yu S , et al. Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol 2008; 116 (6) 625-637
• 35 Mulder DW, Kurland LT, Iriarte LL. Neurologic diseases on the island of Guam. US Armed Forces Med J 1954; 5 (12) 1724-1739
• 36 Bergeron C, Steele JC. Guam parkinsonism-dementia complex and amyotrophic lateral sclerosis. A clinico-pathological study of seven cases. In: Rose FC, Norris FH, Norris FC, , eds. Amyotrophic Lateral Sclerosis: New Advances in Toxicology and Epidemiology. Huntingdon, Cambridgeshire, UK: Smith-Gordon; 1990. 13. 89-98
• 37 Sacks O. The Island of the Colorblind. New York: Alfred A. Knopf; 1997
• 38 Plato CC, Garruto RM, Galasko D , et al. Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 2003; 157 (2) 149-157
• 39 Galasko D, Salmon D, Gamst A , et al. Prevalence of dementia in Chamorros on Guam: relation to age, gender, education and APOE. Neurology 2007; 68 (21) 1772-1781
• 40 Monmaney T. Annals of Science (An Epidemic of Brain Disease). The New Yorker October 29, 1990; 85-113
• 41 Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 2013; 10 (3) 459-472